CareDx To Acquire Transplant Hero Medication Management Application

CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced it has acquired Transplant Hero LLC, a New York-based provider of a mobile application supporting the needs of transplant patients.

The acquisition of Transplant Hero builds on AlloCare, the comprehensive CareDx mobile health app for managing the day-to-day health of patients before and after transplant. Transplant Hero strengthens CareDx’s focus on the transplant patient journey and adds to its growing digital portfolio which includes a robust suite of cloud-based solutions and software for transplant centers and dialysis providers.

Transplant Hero provides a smartphone app focused on helping transplant patients manage their medications through alarms and interactive logging of medication events. Medication management is especially important for transplant patients who must follow a regular regimen to protect against organ rejection. The number of pills and the complexity of the regimen often makes medication management a challenge. The app offers support to various types of organ recipients, including kidney, heart, lung, liver, pancreas, and small bowel.

“CareDx and Transplant Hero are both dedicated to improving outcomes for transplant patients,” said Reg Seeto, President and CEO, CareDx. “Transplant Hero’s easy-to-use interface and transplant focus allows us to expand into different organs. We will be able to leverage Transplant Hero’s well-established social media presence to augment AlloCare which has been built around patients from kidney transplant centers.”

“CareDx continues to make a difference in the lives of transplant patients and is a great fit for why Transplant Hero was originally founded. We are looking forward to working together to help improve the lives of individual transplant patients,” said Jay Graham, MD, MBA, FACS, Founder and CEO of Transplant Hero.

SourceCareDx

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version